ALB and neoplasm: The role of inflammation has long been acknowledged as a hallmark during cancerogenesis and tumor progression in malignant disease.7, 8 In the context of tumor-associated inflammation, the systemic inflammatory response is linked with poorer outcomes and as of significant prognostic relevance in various cancer types.9, 10 This systemic inflammatory response is usually measured in the peripheral blood with numbers of differential blood cell counts (lymphocytes, neutrophils, platelets) as well as serum proteins (C-reactive protein, albumin).